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Background: Distinguishing between stroke subtypes and knowing the time of stroke
onset are critical in clinical practice. Thrombolysis and thrombectomy are very effective
treatments in selected patients with acute ischemic stroke. Neuroimaging helps decide
who should be treated and how they should be treated but is expensive, not always
available and can have contraindications. These limitations contribute to the under use
of these reperfusion therapies.
Aim: An alternative approach in acute stroke diagnosis is to identify blood biomarkers
which reflect the body’s response to the damage caused by the different types of stroke.
Specific blood biomarkers capable of differentiating ischemic from hemorrhagic stroke
and mimics, identifying large vessel occlusion and capable of predicting stroke onset
time would expedite diagnosis and increase eligibility for reperfusion therapies.
Summary of Review: To date, measurements of candidate biomarkers have usually
occurred beyond the time window for thrombolysis. Nevertheless, some candidate
markers of brain tissue damage, particularly the highly abundant glial structural proteins
like GFAP and S100β and the matrix protein MMP-9 offer promising results. Grouping
of biomarkers in panels can offer additional specificity and sensitivity for ischemic stroke
diagnosis. Unbiased “omics” approaches have great potential for biomarker identification
because of greater gene, protein, and metabolite coverage but seem unlikely to be the
detection methodology of choice because of their inherent cost.
Conclusion: To date, despite the evolution of the techniques used in their evaluation, no
individual candidate or multimarker panel has proven to have adequate performance for
use in an acute clinical setting where decisions about an individual patient are being
made. Timing of biomarker measurement, particularly early when decision making is
most important, requires urgent and systematic study.
Keywords: stroke, biomarker, review, microarray, acute
BIOMARKERS
Use of the term “biomarker” describes measures of biological function was first seen in Medline is
1977 and has exploded in the last decade (1). A US National Institutes of Health working group
defined a biomarker as: “a characteristic that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
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intervention” (2). While the term “biomarker” can include
clinical or imaging measurements, it is usually reserved for
describing molecules found in bodily fluids (1).
Biomarkers such as cardiac troponin, creatine kinase, or D-
dimer are used in practice in the emergency department for
the diagnosis and early management of the life-threatening
conditions including myocardial infarction or pulmonary
embolism. Indeed, D-dimer measurements are used for the
exclusion of a diagnosis of pulmonary embolism with a
sensitivity of 96%. A negative D-dimer test will virtually rule
out thromboembolism (3). Cardiac troponin (and especially the I
isoform) is used routinely to diagnose myocardial infarction with
a sensitivity of more than 90% for a cut off value of 0.04 ng/ml (4).
Other biomarkers are used as tools for disease stating (e.g.,
carcinoembryonic antigen-125 for cancers), for classification
of disease severity (e.g., blood prostate-specific antigen
concentration to indicate prostate cancer growth and
metastasis), to assess disease prognosis (e.g., measurement
of tumor shrinkage) or to aid therapeutic monitoring (e.g., blood
cholesterol concentrations during therapy to reduce the risk of
heart disease) (2).
THE NEED FOR ACUTE STROKE
BIOMARKERS
Five interventions improve outcome in patients with ischemic
stroke. These are thrombolysis with recombinant tissue
plasminogen activator (rt-PA) (5), aspirin given within 48 h
(6), management of the patients within a dedicated stroke unit
(7), hemicraniectomy (8), and more recently endovascular clot
retrieval (9).
Thrombolysis is currently recommended for IS patients that
present within 4.5 h of stroke onset. Advanced neuroimaging
allows extension of this time window up to 9 h and inclusion
of patients that wake up with stroke symptoms if salvageable
brain tissue can be identified (10, 11). Nevertheless, thrombolysis
is disappointingly infrequent in patients with acute ischemic
stroke. Indeed, <10% of ischemic stroke patients receive this
therapy in most centers and no more than a third in the best
performing centers (12–16). The main reasons for this underuse
are uncertainty about stroke type, how long the ischemia has
been present diagnosis and the associated risks of cerebral
bleeding (17–21).
Thrombectomy is currently recommended in IS patients (after
or independently from rt-PA) with evidence of large vessel
proximal anterior circulation occlusion andwithin 6 (or 24 hwith
advanced imaging selection) of symptoms onset (9, 22–24). This
revolutionary treatment is unfortunately not in more widespread
use than thrombolysis as it is estimated that fewer than 10% of
acute IS patients would meet the eligibility criteria and not all
stroke centers have sufficient resources and expertise to deliver
this therapy (25, 26).
Brain imaging currently plays a critical biomarker role in acute
stroke management as it is the only proven way to differentiate
ischemic from hemorrhagic stroke. Advanced perfusion imaging
can also be used to help select patients that might benefit from
rt-PA or thrombectomy under specific circumstances (10, 11, 23,
24). Nevertheless, imaging cost, availability, contraindications,
as well as the level of expertise required to interpret advanced
imaging results, restricts the global use of reperfusion therapies.
Other less expensive more and accessible stroke biomarkers
detected in the blood would be an important addition to the
stroke clinician’s armory.
An ideal stroke biomarker(s) should be able, with high
specificity and sensitivity, to differentiate hemorrhagic and
ischemic stroke (and clearly distinguish them from stroke
mimics). They should predict stroke prognosis, facilitate
therapeutic stratification and therapeutic monitoring, for
example by indicating risk of hemorrhagic transformation after
stroke or after rt-PA treatment. Moreover, if repeated measures
can be made in a clinically useful time frame, specific stroke
biomarkers could act as a “stroke clock” to aid in assessing time
of stroke onset to increase the number of IS able to benefit from
treatment with rt-PA, especially those who wake-up with stroke.
With the advent of mechanical thrombectomy, brain imaging
with vascular sequences has become a de facto standard in
the management of an acute stroke. Nevertheless, a biomarker
that provides the same information would facilitate and fasten
the access to therapies. It would have the potential to aid
early identification and pre-hospital stratification of ischemic
stroke patients. Indeed, biomarker stratification of the different
classes of stroke patients in a pre-hospital setting would facilitate
directing them to a hospital where thrombectomy is performed
without losing crucial time by performing brain imaging in
the nearest hospital and then transferring the patient to the
comprehensive stroke center. It is known that substantial delays
of 110–128min are associated with secondary transfer vs. the
direct approach (27).
Over 150 candidate stroke biomarkers have been studied for
roles ranging from diagnosis to long term prognosis (28–35).
The following literature review highlights those biomarkers
with the potential to have an impact in the acute clinical setting,
especially with regard to reperfusion therapy. Moreover, in this
acute context, the review has been focused on studies using blood
as a substrate for biomarker research because of the ease with
which this biological fluid can be accessed in the emergency
setting. Table 1 summarizes the most relevant results of this
review. Table 2 highlights the main clinical uses ascribed to the




S100B, a glial protein, highly specific to nervous tissue, was
one of the first molecules suggested as a candidate to aid IS
diagnosis. Hill and colleagues reported a specificity of more
than 95% for S100B measured on the first day of admission
in 28 non-consecutive stroke patients but the measurement
had poor sensitivity (71). More recently, Zhou et al. reported
that measuring S100B within the first 6 h of stroke helped
differentiate IS from ICH (sensitivity of 95.7%, specificity of
70.4%, using a cut-off of 67 pg/ml) (36). Unfortunately, these
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TABLE 1 | Summary of the most relevant studies and results of stroke biomarkers.
Biomarker Function tested Timing of sampling Sensitivity (%) Specificity (%) Cut off value n References
S100B Differentiation between
IS and ICH
Within 6 h of symptom
onset
95.7 70.4 67 pg/ml 71 IS and 46 ICH (36)
Differentiation between
stroke and mimics
24 h after symptom
onset




Within 6 h of symptom
onset
82 46 >0.23 g/l 275 rt-PA treated IS (38)
Risk of malignant
oedema
At 8, 12, 16, 20, and
24 h after symptom
onset
75 (at 12 h)
94 (at 24 h)
80 (at 12 h)
83 (at 24 h)
>0.35 g/l (at 12 h)






Within 4.5 h of symptom
onset





Between 2 and 6 h of
symptom onset
86 76.9 0.7 ng/ml 65 IS and 43 ICH (41)
Differentiation between
IS and ICH
Within 4.5 h of symptom
onset
61 96 34 ng/ml 79 IS and 45 ICH (42)
Differentiation between
IS and ICH
Within 6 h of symptom
onset
77.8 94.2 0.03 g/l 146 I and 46 ICH (43)
Differentiation between
IS, ICH and mimics
Within 6 h of symptom
onset
91 97 0.43 ng/ml 121 IS, 34 ICH, 31
mimics, 5 SAH, and 79
controls
(44)
NSE Favorable outcome after
rt-PA
Within 4.5 h of symptom
onset
77.1 59.4 13.90 ng/ml 67 rt-PA treated IS (45)
MMP-9 Risk of hemorrhagic
transformation after
rt-PA
Within 3 h of symptom
onset
92 74 >140 ng/ml 134 rt-PA treated IS (46)
NR2A/2B aAbs Differentiation between
stroke and controls
Within 3 h of symptom
onset






Within 72 h of symptom
onset
92 96 1.0 µg/l 101 IS, 91 non-stroke and
52 controls
(48)
Apo C-III Differentiation between
IS and ICH
Within 6 h of symptom
onset
94 87 36 16 IS and 15 ICH (49)
Apo C-I Differentiation between
IS and ICH
Within 6 h of symptom
onset
94 73 60 16 IS and 15 ICH (49)
Apo B Differentiation between
stroke and controls
After a period of
overnight fasting for 12 h
96 94 144 mg/dl 50 strokes and 50
controls
(50)
Apo A-I Differentiation between
stroke and controls
After a period of
overnight fasting for 12 h
88 86 114 mg/dl 50 strokes and 50
controls
(50)
Apo B/Apo A-I Differentiation between
stroke and controls
After a period of
overnight fasting for 12 h
98 96 1.2 50 strokes and 50
controls
(50)
PARK 7 Differentiation between
stroke and controls
On admission (median
of 17 h after symptom
onset)






of 17 h after symptom
onset)








Within 12 h of symptom
onset
93 93 7.0 ng/ml 172 IS and 133 controls (52)
c-Fn Risk of hemorrhagic
transformation after
rt-PA
Within 3 h of symptom
onset




time of 6–7 h after
symptom onset)
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TABLE 1 | Continued
Biomarker Function tested Timing of sampling Sensitivity (%) Specificity (%) Cut off value n References
PAI-1 and TAFI Risk of hemorrhagic
transformation after
rt-PA
Within 3 h of symptom
onset
75 97.6 PAI-1 <21.4 ng/mL
and TAFI >180%
77 rt-PA treated IS (54)
Glutamate Risk of early neurological
deterioration
On admission (mean
time of 9–10 h after
symptom onset)




GABA Risk of early neurological
deterioration
On admission (mean
time of 9–10 h after
symptom onset)










Within 12 h of symptom
onset









Within 24 h of symptom
onset







Within 6 h of symptom
onset








Within 24 h of symptom
onset











Within 24 h of symptom
onset
Overall accuracy of the model:
0.91







Within 3 and 6 h of
symptom onset
22.7 80.2 S100B >96 pg/ml
and sRAGE
<0.97 ng/ml
776 IS and 139 ICH (61)
GFAP and RBP4 Differentiation between
IS and ICH
Within 6 h of symptom
onset
– 100 GFAP <0.07 ng/ml
and RBP4 >61
lg/mL
38 IS and 28 ICH (62)
Panel of 22 genes Differentiation between
stroke and controls
<24, 24–48, >48 h after
symptom onset
78 80 – 20 IS and 20 controls (63)
Panel of 18 genes Differentiation between
stroke and controls
Within 3 h, at 5 h and at
24 h after symptom
onset
With accuracy in 66% within 3 h,
86% at 5 h and 100% at 24 h
– 15 IS and 8 controls (64)
Panel of 23 genes Differentiation between
stroke etiologies
Within 3 h, at 5 h and at
25 h after symptom
onset
95.2 95.2 – 15 IS (65)
Panel of 40 genes Differentiation between
cardio-embolic and
large vessel strokes
At 3 h, at 5 h and at 25 h
after symptom onset
>90 >90 – 76 IS (66)
Panel of 34 genes Differentiation between
TIA and patient with
CVD
From 9 to 68 h (mean
35 h) after symptom
onset
100 100 – 26 TIAs and 26 controls (67)
Panel of 26 genes Differentiation between
IS or TIA and controls
Within 72 h of symptom
onset
89 89 – 94 IS, 26 TIAs, and 44
controls
(68)
Panel of 41 genes Differentiation between
lacunar and non-lacunar
strokes
Within 72 h of symptom
onset




early (<3 h) and late (3 h)
presentation of stroke
Within 3 h and after 3 h
of symptom onset
AUC = 0.79; OR = 10 17.7 µg/l 103 IS and 132 controls (70)
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Combination of S100B, MMP-9, vWF, BNGF,
and MCP-1
Combination of S100B, MMP-9, vWF, and
VCAM
Combination of S100B, MMP-9, D-dimer, BNP,
and CRP
Combination of S100B, MMP-9, D-dimer, and
BNP
Combination of MMP-9, D-Dimer, sRAGE,












































Stroke etiology Panel of genes
results were not substantiated by Gonzalez-García’s 2012 study
where S100B, measured between 8 and 48 h of symptom onset
was significantly elevated in stroke compared to controls but
failed to differentiate between IS and ICH and did not correlate
with stroke severity on admission (72) despite other studies
suggesting that S100B concentrations correlated with stroke
severity and size of infarction (73–75).
Serum S100B concentration measured 24 h after symptom
onset is significantly higher in stroke patients (posterior
circulation IS or infratentorial ICH, no distinction was made in
the analysis) than in controls or in patients with vertigo from
non-vascular causes (37). However, in addition to prolonged and
delayed release into the blood after stroke, S100B levels are also
increased in other neurological pathologies such as traumatic
brain injuries and extracranial malignancies (76, 77).
Never-the-less, elevated S100B concentration (>0.23 g/l) has
been associated with hemorrhage risk due to rt-PA treatment
(specificity of 82%, sensitivity 46%) (38) suggesting with further
work, this biomarker may have some utility.
GFAP
GFAP (glial fibrillary acidic protein), another glial protein specific
to astrocytes (78), is the best candidate to date for differentiating
hemorrhage and ischemic stroke. Based on detection of delayed
GFAP release in patients with ischemic stroke (maximum
concentration reached 2–4 days after ischemic stroke onset),
Foerch and his team studied this molecule in different clinical
settings and showed promising results (79–81). In a multicenter
clinical study of 205 patients (163 with IS, 39 with ICH
and three stroke mimics) diagnostic accuracy was high for
differentiating intracerebral hemorrhage from ischemic stroke by
GFAP immunoassay on a single blood sample obtained within
4.5 h of symptom onset. Using GFAP cut-off of 2.9 ng/l provided
a specificity of 96.3% and a sensitivity of 84.2% for distinguishing
ICH, IS and stroke mimics (40). In addition, the levels of
GFAP were shown to be correlated with the hemorrhage volume
(40, 79, 80).
Several studies have confirmed the potential for serum GFAP
to distinguish IS and ICH. Xiong et al. showed that the GFAP
concentration in blood collected within 2–6 h after symptom
onset was significantly higher in ICH (n = 43) than IS (n =
65) patients, with 86 and 76.9% sensitivity and specificity of,
respectively, using a cut-off point of 0.7 ng/ml) (41). Ren et al.
replicated these findings using a GFAP cut off value of 0.34 ng/ml
with 61% sensitivity and 96% specificity in a 4.5 h time window
from symptoms onset (42). A later study measuring serum GFAP
in 46 ICH and 146 IS patients reported 77.8 and 94.2% sensitivity
and specificity distinguishing the two stroke subtypes using a
cut-off value of 0.03 g/l within 6 h of diagnosis (43).
Similarly, Katsanos et al. reported that in samples from
patients presenting within 6 h from symptoms onset, significantly
raised median plasma GFAP concentrations detected in ICH
vs. IS, stroke mimetics, and controls. A cut-off of 0.43 ng/mL
provided the best threshold for differentiation between ICH
and AIS (sensitivity of 91% and specificity of 97%). They also
described that the best timing of sampling to allow optimal
differential diagnostic between IS and ICH was in the second
hour from symptom onset (44).
A meta-analysis including nearly 1,300 patients confirmed
the potential of measuring GFAP in the blood in the early
phase of stroke (samples drawn <3 h from symptoms onset),
to discriminate IS, ICH and mimics. Interestingly, there was no
significant difference in diagnosis accuracy when patients were
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FIGURE 1 | Sources of the major candidate biomarkers.
classified in three subgroups according to time of sampling (0–60,
60–120, 120–180min after stroke onset) (82).
More recently, in a smaller meta-analysis including 340
patients (236 acute IS and 104 ICH) from four studies, Cabezas
et al. confirmed that standardized levels of GFAP blood levels
were significantly elevated in ICH compared with IS. Here again,
the analysis showed no correlation of GFAP concentration with
time of sampling (83).
Controversially, it was previously reported that when
measured early (<1 h after stroke onset), serum GFAP did not
distinguish ICH and IS (80).
Nevertheless, GFAP measurement is not part of routine
clinical practice. The results described above need to be replicated
by different groups in larger studies with standardization
of detection methodologies and diagnostic cut-offs. This is
especially important with respect to the differentiation of stroke
mimics as GFAP has also been found in the serum from high-
grade glioma patient (84) and is considered as a potential
biomarker for diagnosis of traumatic brain injuries (85) which
are both potential stroke mimics. Ideally GFAP sensitivity and
specificity to distinguish hemorrhagic from ischemic stroke
would need to be consistent across time, especially in the
earliest time point from symptoms onset when the distinction
is most important prior to initiation of thrombolytic therapy.
If this is not the case, it will constitute a major barrier for
therapeutic triage, especially in a prehospital setting, where
timing of stroke evolution may still be uncertain. Refinement of
GFAP measurement technologies and application strategies will
be required.
NSE
Serum concentrations of NSE (neuron-specific enolase) have
been reported to be as significantly raised in stroke patients
compared to controls and to correlate with infarct size and
stroke symptom severity (75, 86–88). Serum NSE levels assessed
prospectively within 4.5 h of IS symptom onset in rt-PA threated
patients (n = 67) correlates with NIHSS at 24 h (R = 0.342),
and lower serum NSE levels and NIHSS scores were detected in
patients with favorable neurological outcomes after 90 days (45).
Overall, NSE has a similar discriminatory profile to S100B
(high specificity and low sensitivity) (71–73, 88). This may in part
be due variable kinetics of release, sometimes peaking 24 h after
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stroke (89, 90). Interestingly, Kim et al. showed that IS patients
identified as having a second peak of serum NSE (20% of the
studied population) were more at risk of developing hemorrhagic
transformation (OR = 6.8) (90). Therefore, while NSE is not
currently recommended for the diagnosis of acute stroke it may
still have clinical potential.
MMP-9
Expectations have been high for MMP-9 (matrix
metalloproteinase-9) as a stroke diagnostic biomarker because
of its role in response to brain injury via its involvement
in extracellular matrix degradation. MMP-9 concentrations
measured acutely have been linked increased to infarct size,
worse neurological outcome, and complications of hemorrhagic
transformation (46, 91–96). Serum MMP-9 concentrations
≥140 ng/ml were shown to predict hemorrhagic transformation
in rt-PA treated ischemic stroke patients (sensitivity 92%,
specificity 74%) (46). Six other studies confirmed the correlation
between MMP-9 concentration and increased bleeding risk
after rt-PA (96). Similarly, Barr et al. identified an association
between elevated serum concentrations of MMP-9 and blood
brain barrier disruption which is a key feature of hemorrhagic
transformation (97). However, the rise of MMP-9 is not specific
to ischemic stroke, moreover its concentration is reported to
peak at 24 h post stroke (96), too late for making decisions about
thrombolysis, and standardization of MMP-9 measurements and
experimental replication are still required.
NMDA-R
Autoantibodies to the glutamate NMDA-R (N-methyl-D
aspartate receptors; NR2A/NR2B subunits) associated with
neurotoxicity are elevated after stroke and distinguish IS patients
(n = 31) from controls 3 h after symptoms onset with 97%
sensitivity and 98% specificity (47). In a different cohort, plasma
levels of NMDA-R NR2A were also shown to be elevated in
ischemic strokes when there was no difference observed in
patients with cerebral hemorrhage in comparison to controls
(98). Criticism for the potential use of NMDA-R antibodies
for the diagnosis of ischemic stroke were raised as NMDA-
R antibodies have also been detected in patients with prior
stroke hypertension, atherosclerosis, epilepsy, systemic lupus
erythematous, and encephalitis (47, 98–100). Nevertheless, more
recently, NR2 peptide (a product of degradation of NMDA-R) in
blood has been reported to distinguish IS from stroke mimetics,
patients with vascular risk factors and controls with 92 and 96%
sensitivity and specificity, respectively (48). On the negative
side, NR2 levels might not be increased in lacunar and small
cortical strokes (48). Interestingly, detection of NMDA-R NR2A
antibodies and NR2 concentrations might have a temporal
profile after ischemic stroke (with a peak after 12 h) (48, 98)
that might contribute to pinpointing a patients stage of stroke
evolution but these results need to be validated in specifically
designed studies.
Apo-lipoproteins
Some members of the apo-lipoprotein family have also been
tested as potential biomarkers for IS diagnosis. Apo C-I and Apo
C-III concentrations were found to be increased in IS compared
to ICH within 6 h of symptom onset and both were reported to
have the potential to discriminate IS from ICH. For Apo C-III
this was achieved with 94 and 87% sensitivity and specificity,
respectively (49). A panel of nine apo-lipoproteins was tested
as a tool to distinguish IS and ICH patients within the first
week after symptom onset using a mass spectrometry assay. Apo
C-I and Apo C-III reported to provide the best classification
power as individual markers but combining Apo C-III and
Apo A-I provided the best discrimination overall (AUC = 0.92)
(101). Unfortunately, these results were not confirmed by Walsh
and colleagues who looked at a broader panel which included
paraoxonase-1, MMP- 3 and 9 and Apo A-I, C-I, and C-III for
their ability to distinguish between IS, ICH patients and controls
on blood samples obtained within 12 h of symptom onset. In
this cohort, the levels of Apo A-I, Apo C-I, and paraoxonase-1,
were shown to be lower in IS than in ICH patients with the other
candidates having no discriminatory value (102). It is intriguing
to speculate that this stark difference might be accounted for by
a temporal component to the expression profile that might itself
be useful.
Others have taken a ratio-metric approach to the use of
apo-lipoprotein family members as stroke biomarkers. As et al.
reported that Apo B concentrations and the Apo B/Apo A-I
ratio were significantly elevated while levels of Apo A-I was
significantly decreased in IS patients compared to controls.
All three-potential biomarker tests were reported to have a
high specificity and sensitivity to discriminate stroke patients
(between 86 and 98%) (50). The Apo B/Apo A-I ratio has also
been associated with early neurological deterioration in large
artery atherosclerotic stroke, this was not found for other stroke
subtypes (103).
Others
Other less well-studied candidates may also have merit. For
example, Allard et al. described first in 2005 the potential
of PARK7 and NDKA (nucleoside diphosphate kinase A) as
biomarkers for stroke diagnosis as their plasma concentrations
increased early after symptom onset (29, 104). However, their
specificity and sensitivity as markers were dependent on the
diagnostic cut-off values used (104) and the results still need to be
replicated. Tulantched et al. later specified that PARK7 seemed to
have a better prognostic value thanNDKA, both in sensitivity and
specificity. Once more, collection time in this prospective study
was late after stroke onset with a median of 17 h (51).
More recently, a prospective study found that glycogen
phosphorylase isoenzyme BB measurements were able to
discriminate between 172 IS and 133 controls with 93%
sensitivity and specificity (cut-off of 7.0 ng/mL and sample drawn
within 12 h of onset) (52). Nevertheless, glycogen phosphorylase
which metabolizes glycogen to provide glucose-1-phosphate to
restore energy stores has also been identified as a potential marker
of ischemic myocardial injury (105, 106).
A meta-analysis interrogating over 130 biomarkers published
by Hasan et al. in 2012, concluded that C-reactive protein (CRP),
P-selectin and homocysteine were the only three biomarkers
able to significantly differentiate ischemic stroke from healthy
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patients (28). Nevertheless, once more, these three molecules
have a low specificity for ischemic stroke and therefore preclude
their diagnostic use in acute stroke situations.
A systematic review performed by Misra et al. identified 10
single biomarkers and seven biomarker panels with a potential
for differentiating IS and ICH. Once more, GFAP appeared to
perform well, either as a single marker or in association either
with the Activated Protein C- Protein C Inhibitor Complex
(APC-PCI) or with the Retinol Binding Protein 4 (RBP4).
Nevertheless, because the time of sampling was outside of the
time window for practical acute stroke intervention (31), their
clinical utility is still unclear. In another systematic review,
Monbailliu and colleagues identified a different pairing of
diagnostic biomarkers for consideration. BNP and S100 were the
only two blood-based proteins biomarkers in their study that
could differentiate IS from ICH, stroke mimetics and healthy
control subjects (32).
The most recent meta-analysis published in 2020 analyzed 25
biomarkers across 40 studies and over 5,000 IS, 750 ICH, 550
mimics, and 1,770 healthy controls on samples collected within
24 h of symptoms onset. BNP, MMP-9, D-Dimer were identified
to significantly differentiate the different patient groups while
GFAP was successful to differentiate IS from ICH within 6 h.
S100B, caspase-3 and NSE only distinguished IS from stroke
mimics. Nevertheless, the authors highlighted that 67% of the
studies included had only moderate study quality suggesting the
need for further well-conducted studies (107).
While these markers all offer promise as diagnostic aids, until
larger validation studies tease out the reproducibility of diagnosis,
specificity in different patient groups and the role of sampling
window in the value of the measurements, the current level of
uncertainty does not recommend their immediate clinical use.
BIOMARKERS OF DISEASE
PROGRESSION
In addition to the previously mentioned MMP-9, NSE, and
S100B, other molecules are linked with increased bleeding
risk after IS. Plasma levels of c-Fn (cellular-fibronectin),
which reflect vascular damage, have been associated with the
development of hemorrhagic transformation following t-PA use
(108). When evaluated in a second cohort of 27 subjects, serum
c-Fn ≥3.6µg/ml identified hemorrhagic transformation with a
sensitivity of 100% but specificity of 60% (46). Combining c-Fn
with MMP-9 allowed detection of hemorrhagic transformation
with 92% sensitivity, 87% specificity, and a positive predictive
value of 41% (46). Reduced levels of PAI-1 (plasminogen
activator inhibitor) and higher levels of TAFI (thrombin-
activated fibrinolysis inhibitor), two endogenous fibrinolysis
inhibitors, have been associated with symptomatic intracranial
hemorrhage after thrombolysis therapy. When combined, PAI-
1 level <21.4 ng/ml and a TAFI level >180% predicted
symptomatic intracranial hemorrhage after rt-PA (sensitivity and
specificity of 75 and 97.6%, respectively) (54).
Several biomarkers have been associated with early
neurological deterioration (END). This has been defined as
neurological worsening between 48 and 72 h after admission and
occurs in one third ischemic stroke patients (109). Cytotoxic
mechanisms mediated by glutamate, nitric oxide, and cytokines
and endothelial-leukocyte adhesion molecules have been
proposed as mediators of progression of tissue damage (110).
High plasma glutamate concentrations have been correlated
with neurological worsening and infarct growth at 72 h after
stroke onset (55, 110). Plasma glutamate concentrations of
>200 µmol/l on admission have a positive predictive value for
neurological deterioration at 48 h after lacunar infarction of
67% (55). Plasma GABA levels <240 nmol/l on admission also
had a positive predictive value for neurological deterioration
at 48 h after lacunar infarction of 84% (55). Higher levels of
inflammatory markers such as ferritin, IL-6 (interleukine-6),
TNF-α (tumor necrosis factor-α) and ICAM-1 (intercellular
adhesion molecule-1) were also shown to be associated with early
neurological worsening (110–112).
Space-occupying brain oedema (also called malignant
oedema), an early life-threatening problem in patients with
large hemispheric stroke, has been shown to be predicted by an
elevated plasma S100B level (>0.35 g/l) with a 75% sensitivity
and a 80% specificity at 12 h after stroke and even more at
24 h (94 and 83% sensitivity and specificity, respectively) (39).
c-Fn and MMP-9 concentrations have also been found to be
significantly higher in patients with malignant MCA (m-MCA)
infarction than in controls. c-Fn concentrations of >16.6µg/ml
provided a 90% sensitivity and 100% specificity with 89 and
100% negative and positive predictive values, respectively, for
prediction of m-MCA infarction (53).
While more work is needed to determine precisely when
in a patient’s clinical course these measurements first provide
valuable information about that individual’s likely outcome, their
generally high sensitivity and specificity suggest they will find
clinical utility.
BIOMARKERS PANELS
To better account for the molecular complexity of the ischemic
cascade and increase the sensitivity and specificity of biomarkers
as diagnosis tools, many researchers have also investigated
biomarker panels, evaluating multiple molecules simultaneously
instead of looking for a single biomarker. In a systematic review,
Whiteley et al. identified seven panels of biomarkers tested
as ischemic stroke diagnostic tools. The main criticisms were
that the multimarker panel studies did not provide regression
equations for stroke prediction and that a variety of cut-off
values were used for the same biomarker. Moreover, the sample
collection time points usually occurred outside the window
where treatment was possible (29).
Reynolds et al. assessed plasma from 223 stroke patients
(including IS, ICH and subarachnoid hemorrhage) and
214 healthy controls for more than 50 serum biomarkers
using ELISAs (enzyme-linked immunosorbent assay). The
combination of S100B, B-type neurotrophic growth factor
(BNGF), von Willebrand factor (vWF), MMP-9, and monocyte
chemotactic protein-1 (MCP-1) provided diagnosis of stroke
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within 12 h after symptom onset with a 91% sensitivity and a
97% specificity (56). A related panel of S100B, MMP-9, vWF, and
vascular cell adhesion molecule (VCAM) studied by the same
group of researchers in 65 suspected ischemic stroke patients
and 157 controls within 24 h of symptoms provided a sensitivity
and specificity of 90% (57).
In 130 patients with acute focal neurologic deficits admitted
within 6 h of onset of symptoms, a panel including D-dimer,
CRP, B-type natriuretic protein (BNP), MMP-9, and S100B was
predictive of ischemic stroke with sensitivity and specificity of
81 and 70%, respectively (58). While less specific and sensitive
than the preceding panels, its time window of application is more
appropriate to the acute stroke setting (6 vs. 24 h). However,
when the same panel of markers, excluding CRP, was tested in
a prospective multicenter trial of more than 1,100 patients who
presented with symptoms suggestive of stroke, a 86% sensitivity
and 37% specificity were achieved for distinguishing stroke from
mimics in the first 24 h after symptom onset (59).
In a study published in 2011, Montaner et al. tested, in an
ED setting, a panel of blood biomarkers including CRP, S100B,
MMP-9, a soluble receptor for advanced glycation end products
(sRAGE), D-Dimer, brain natriuretic peptide (BNP), caspase-
3, neurotrophin-3, chimerin, and secretagogin. They identified
levels of caspase-3, D-dimer, sRAGE, chimerin, secretagogin,
and MMP-9 as independent predictors of stroke vs. mimics.
Moreover, they reported a predictive probability for identifying
stroke of 99.01% by combining set cut-off values of these six
biomarkers (60). The same team have also demonstrated, in
a cohort of 915 stroke patients, that just S100B and sRAGE,
could distinguish between IS and ICH with an AUC of 0.76 for
blood samples obtained within 3 h after symptom onset. This
was confirmed in blood samples obtained within 6 h of symptom
onset (61).
More recently, measurement of retinol binding protein 4
(RBP4) (with a cut off value >61 g/ml) and GFAP (with a cut off
value of<0.07 ng/ml) was shown to distinguish IS from ICHwith
a specificity of 100% in a cohort of 38 IS and 28 ICH samples (62).
In the STROKE-CHIP study, a prospective multicenter study
of over 1,300 patients, published in 2017, Bustamante et al.
studied a panel of 21 biomarkers selected from prior studies
and published literature (including S100B, cFn, NSE, MMP-9
e.g.) on blood samples collected immediately upon arrival of
patients presenting within 6 h after symptom onset. None of
these biomarkers were able to provide an accurate hyperacute
differential diagnosis of stroke (113).
While adding complexity to the laboratory work required,
panels of markers appear to have the potential to offer significant
improvements in specificity and sensitivity. However, further
validation is still clearly required.
THE mRNA REVOLUTION
The development of oligonucleotide microarray techniques, and
more recently RNAseq, opened new perspectives in the quest for
discovery of specific acute stroke biomarkers. These techniques
allow unbiased investigation of the entire transcriptome as RNA
shed from damaged or communicating cells, or contained within
the cells of the immune system, the body’s own “first responders”
to injury. In addition, changes in mRNA expression occur
very quickly often before changes of protein expression can be
detected (114). This suits perfectly the acute ischemic stroke
setting where “time is brain.”
Tang and colleagues reported a blood genomic response
specific to ischemic stroke on blood samples collected at 24 h
from rats subject to MCAo, sham surgery, and naïve controls.
Twenty five genes were shown to be significantly (more than
2-fold) over expressed in rat blood 24 h after induction of
ischemia while 98 had decreased significantly in comparison to
controls (115).
Using blood samples collected from 20 patients with ischemic
stroke and in 20 controls and stratified for sampling time
(<24 h n = 7, 24–48 h n = 10, and >48 h n = 3), Moore and
colleagues found that, after correction for multiple comparisons,
190 genes were differentially expressed (comparing stroke and
control). Moreover, a panel of 22 genes identified as coming
from peripheral mononuclear cells differentiated ischemic stroke
from controls with 78 and 80% sensitivity and specificity,
respectively (63).
When bloods were sequentially collected within 3 h, at
5 h and at 24 h from eight controls and 15 ischemic stroke
patients [initially enrolled in the Combination approach to Lysis
utilizing Eptifibatide And Recombinant tissue-type plasminogen
Activator (CLEAR) trial], 104 genes were identified to have a
1.5-fold change between ischemic stroke and controls at 3 h,
1,106 at 5 h and 906 at 24 h. An 18-gene panel distinguished
between ischemic stroke and controls with accuracy in 75% of
the cases or more at all 3 different time points (64). Genes
included in this panel reflected the involvement of inflammation
in the ischemic pathway but were different from those
identified by Moore.
When samples from the CLEAR trial were used to explore
RNA expression after different ischemic stroke etiologies, 77
genes showed at least a 1.5-fold change in expression between
large vessel occlusion and cardioembolic strokes. Twenty three
of these genes could distinguish these etiologies with >95%
sensitivity and specificity (65).
However, when RNA isolated from the peripheral blood
mononuclear cells of acute ischemic stroke patients, stroke
survivors and patients with acute traumatic brain injury was
analyzed (cohort n = 15–20, sampling time: 24–27 h after event
onset), no significant differences in single genes expression
were identified between these groups. Nevertheless, expression
of PDE4D (phosphodiesterase 4 D), an enzyme metabolizing
cyclic adenosine monophosphate in inflammatory cells, was
significantly different between acute ischemic stroke patients and
healthy controls with cardiovascular risk factors (116).
A retrospective case-control study of 39 ischemic stroke
patients and 25 controls (sampling time 10 ± 6.5 h), identified
nine genes whose expression was significantly different in stroke
patients and involvement of toll-like receptor signaling in the
ischemic cascade (117). Five of these nine genes; MMP9, ARG1,
CA4, LY96, and S100A12, had previously been reported as
specific for stroke (64).
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In a larger cohort of 194 blood samples collected at 3, 5,
and 24 h after stroke from 76 patients with acute IS, a 40-gene
panel distinguished cardio-embolic from large vessel strokes with
>95% sensitivity and specificity. In addition, a 37-gene panel
was identified to be able to differentiate atrial fibrillation from
non-atrial fibrillation causes of cardioembolic stroke with >90%
sensitivity and specificity (66).
Zhan and colleagues took a different approach and compared
TIAwith ischemic stroke. In rats they showed that only brief focal
ischemia was needed to induce the majority of changes caused by
ischemic stroke (118).When the same group compared the blood
expression profiles of TIA patients (n = 26) and control subjects
with vascular risk factor but without symptomatic cardiovascular
disease (n = 26), they identified 449 genes that distinguished
between the two groups. Thirty-four genes separated TIAs from
controls with 100% sensitivity and specificity. In addition, two
different patterns of gene expression were identified by cluster
analysis for the TIA patients suggesting a heterogeneous response
to the event between patients and a possible relation with a higher
risk of stroke (67).
These findings were soon tested in a bigger cohort by Jickling
and colleagues. In 164 blood samples collected within 72 h of
symptom onset from stroke, TIA and control patients, 145 genes
were differentially expressed between TIA and controls and 413
genes were significantly different between IS and controls. More
importantly, 74 of the 145 genes identified in the TIA group
were also found in ischemic stroke patients. Twenty six of these
74 common genes were used as a panel to distinguish stroke
and TIA from controls with 89% sensitivity and specificity.
Pathways analysis revealed that the genes common to stroke
and TIA were involved in innate and adaptive immune systems
activation involving B-cells and granulocytes (68). Unfortunately,
the authors did not reveal the composition of their 26-gene panel,
so comparison with the 34-genes panel identified earlier by Zhan
et al. is not possible.
Jickling et al. also evaluated the gene expression profile of
lacunar strokes. In a cohort of 30 lacunar and 86 non-lacunar
strokes (with blood sampling within 72 h of stroke onset), they
identified a 41 genes discriminating lacunar and non-lacunar
stroke with >90% sensitivity and specificity (69).
In 2012, Oh et al. performed microarray analysis on blood
samples collected from 12 ischemic stroke patients and 12
controls (sampling time 12.7 ± 5.3 h after stroke onset). They
identified 88 transcripts with a 1.5-fold change in ischemic stroke
compared to controls and 11 transcripts with 2-fold difference
(including MMP9, Il1R2). Then, they validated the expression
of the three most differently expressed genes (MMP9, Il18RAP,
and GNLY) by quantitative polymerase chain reaction (qPCR).
In another cohort of 120 ischemic stroke patients and 82 controls
(sampling time 10.4 ± 9.7 h). MMP9 concentrations measured
using ELISA were significantly greater in IS compared to controls
but did not to correlate with infarct volume (119).
When quantitative PCR was used validate the expression
profiles of 40 candidate biomarkers identified in previous
studies (63, 64, 117) in 18 ischemic stroke patients and 15
controls (median time of blood sampling 36 h), 16 genes
were significantly upregulated in ischemic stroke patients in
comparison to controls. Six gene clusters were reported to
discriminate between stroke and controls and one of them,
containing seven transcripts, was reported to show high accuracy
for stroke classification (120).
In common with the candidate protein biomarker studies
described earlier, the investigators for the transcriptome studies
summarized above have tended (samples from the CLEAR trial
are an obvious exception) to perform analyses relatively late
in stroke evolution, when diagnosis is generally already certain
and decisions about therapy already made. Moreover, there has
been little emphasis on distinguishing ischemic and hemorrhagic
stroke, or identifying genes that might identify a heightened risk
of bleeding. These gaps in the analysis are surprising. Array
technologies also lend themselves to collaborative re-analysis,
indeed many publishers stipulate that array data be made freely
available. It is therefore also surprising that pooled analysis of the
available data has not yet been performed.
BIOMARKERS OF A STROKE CLOCK
As mentioned above, stroke biomarker discovery has rarely
focused on early temporal change, despite the dynamic
characteristics of stroke. The possibility that changes in
expression of candidate biomarkers with time might help predict
stroke evolution and act as a biological stroke clock which
could allow more patients to be recruited to thrombolysis is
largely unstudied.
In serial blood samples collected at 3, 6, 12, 18, 24, 48, 72, 96,
and 120 h after onset of stroke symptoms, NSE concentration,
measured by immune-assay, rose in the first 2–3 h, then fell
until 12 h before a second elevation that was maintained until
measurement ended on day 5. Tau concentration showed a
continuous increase from admission onward (87).
During a study evaluating the diagnostic performance of
29 pre-selected molecules within the therapeutic window
for thrombolysis in 103 stroke and 132 control patients,
glutathione S-transferase-π (GST-π), an enzyme providing
protection against oxidative stress, was the most significantly
elevated molecule in stroke patient blood. Importantly, GST-
π measurement allowed the discrimination of early (<3 h) and
late (>3 h) presentations of stroke in 90% of the cases with
a cut-off value of 17.7 µg/l. Indeed, GST-π concentration was
almost immediately after stroke with increases detected within
3 h after symptom onset and within 1 h in some. Importantly,
GST-π concentration decreased rapidly after 3 h reaching a
concentration close to normal levels by 6 h after stroke symptoms
onset. When GST-π was measured in a cohort of thrombolysed
stroke patients (blood collected within 3 h after stroke onset, n
= 100), its concentration was elevated above the threshold of
17.7 µg/l in 98% of the cases. A similar but less striking pattern
was observed for PARK7and NDKA (70).
Conversely, in plasma samples collected at 12, 24, and 48 h
after symptoms onset in 39 patients with ischemic stroke, while
MMP-9 concentrations were greater in stroke patients than the
reference interval for healthy controls, no significant changes
were reported over time (95).
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Others have collected human blood samples sequentially in
the same patient early after stroke, but the analysis focused on
creation of a diagnostic tool able to differentiate IS patients from
controls and blood samples were not collected within 3 h after the
ischemic event (results presented previously) (64).
To date, these are the only investigations identifying blood
born biomarkers with a potential to contribute to development
of a stroke clock and a potential ability to discriminate eligible vs.
ineligible patients for reperfusion therapy.
Nevertheless, clinical trials for the discovery of diagnostic
stroke biomarkers suitable for use in the hyperacute phase
of the disease are underway. Some of these trials hope to
identify biomarkers that will aid stroke diagnosis on admission
to the clinic.
The multicenter, observational Biomarkers of Acute Stroke
Etiology (BASE) study aims to identify biomarkers defining acute
IS etiology and is recruited patients presenting within 24 h of
symptom onset. Blood samples are being obtained on arrival and
24, and 48 h later, and gene expression profiling is being used to
identify biomarker candidates of stroke (121).
Results of the innovative Blood And Clot Thrombectomy
Registry And Collaboration (BACTRAC) trial could also lead
to new findings in the stroke biomarker field. Fraser et al.
aim to collect intracranial thrombus material and arterial blood
collected before, after and during mechanical thrombectomy to
allow gene expression and proteomic analysis of the early human
molecular response to ischemic stroke (122).
The Helsinki Ultra-acute Stroke Biomarker Study even
sampled in a pre-hospital setting via blood samples taken by
emergency medical service clinicians during transit to analyze
GFAP and NR2 peptide levels explore novel markers. The
recruitment phase is over but the study has yet to report on the
primary outcomes (123).
CONCLUSIONS
Improving in patient outcomes in acute stroke requires a rapid
and accurate diagnosis of stroke and its subtypes. A biomarker
that could differentiate between hemorrhagic and ischemic
stroke or risk of subsequent bleeding would, in theory, permit
widespread initiation of thrombolysis in the ambulance and save
valuable time and brain tissue.
Markers of brain tissue damage, particularly the highly
abundant glial structural proteins like GFAP and S100β and
the matrix protein MMP-9 offer this promise but have not yet
been systematically evaluated at the earliest time points which
matter most. To date, other highly abundant structural proteins
such as those characteristic of axons, dendrites, and synapses
or oligodendrocyte processes have rarely been considered for
this role with the exception of the NR2 degradation product
of the NMDA receptor and PARK7 which has a specific anti-
oxidant role.
Whether such molecules will be able to rule out stroke
mimics which also damage the structure of the brain remains
to be determined. In this regard, the circulating apolipoproteins
(Apo A1, Apo C1, and Apo C111) and c-FN, PAI-1, and TAFI
which may specifically react to the hematological changes of a
hemorrhagic stroke or hemorrhagic transformation, respectively,
require further study. Accurate prediction of poor outcome after
stroke would help patients, their families and clinicians to make
early and informed decision about choices between rehabilitation
and palliative care.
The suggestion that autoantibodies to NMDA receptors might
help in this task raises the question of whether their presence
in ischemic stroke signifies previous undetected ischemic events
and thus heightened stroke risk. Patients with acute minor IS or
TIA are at risk of further occlusive vascular events, particularly
recurrence of stroke (124, 125). Prognostic scores based on
clinical characteristics observed when first assessed, such as the
ABCD2 score (126), tend to predict early stroke recurrence risk
but they do not discriminate perfectly between those individuals
who will have a recurrent stroke and those who will not (127).
Specific biomarkers which helped stratify this risk would be of
considerable value but might be of little use in diagnosis of first
ever stroke.
If selecting candidate biomarkers based on prior knowledge
of involvement in stroke pathophysiology has yet to prove
successful, the high costs of “omic” discovery strategies has
limited the scope of their use and is still in its infancy. Developing
panels of markers from either source and developing ratiometric
approaches to analysis seem to offer the hope of significantly
better specificity and sensitivity.
For both strategies, most measurements made to date have
been performed later than the clinically critical thrombolysis
and thrombectomy time window. Timing of biomarker
measurement, particularly early when decision making is most
important, requires urgent and systematic study. The kinetics of
change may be revealing in their own right and, if a biomarker
stroke clock can be constructed, might dramatically broaden the
utility of thrombolysis and thrombectomy.
The recent discoveries in advanced cerebral imaging and the
subsequent extension of time window for both thrombolysis and
thrombectomy highlight that specific biomarkers of penumbra
would be even more crucial than biomarkers of time for
therapeutic decision making in the acute setting. Research
combining imaging and biological biomarkers is needed.
The ultimate aim of the stroke biomarker research is the
development of a point of care device. A quick and reliable
bedside biomarker assessment would revolutionize the acute
stroke management. It could potentially expedite the diagnosis
of ischemic stroke by making the imaging step redundant
and aid the clinical decision-making (even in a prehospital
setting). It will reduce time from symptoms to initiation of
reperfusion therapies. Specific biomarkers could also be used
for pre-hospital stratification of important subgroups. Indeed,
they might help identify patients with large vessel occlusion
and facilitate direct access to comprehensive stroke centers and
timely thrombectomy. Stroke biomarkers could help to resolve
the mothership vs. drip and ship dilemma.
Most of the candidate biomarkers described in this review
have been detected by what are best described as research tools
(e.g., ELISA, Western Blotting, Mass Spectrometry, Gene array,
RNASeq) which have inherently long lead times before a result
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might be available for a clinician to use. However, a range of assay
systems are capable of providing results within minutes, both in
a laboratory and point of care setting.
Good examples of rapid assays that could be adapted for stroke
biomarker detection include a range of widely used clinical tests
based on the principles of sandwich ELISA, in which a target
protein is first captured to the surface of the assay device and
then detected by a second antibody bearing an easily detected
label (128). Perhaps the best known of these are pregnancy
tests that detect human chorionic gonadotrophin within a few
minutes of sample application (129). Numerous point of care
immune assays for biomarker detection are currently under
evaluation (130).
Other assay methodologies also have potential for rapid
detection of stroke biomarkers. For example, blood glucose can
be detected even more rapidly (5 s) by using electrochemical
detection of the reaction products of glucose oxidase activity
(131). Miniaturization now also makes highly sensitive and
selective and rapid analyte detection by a range of mass
spectrometry protocols possible, even at the bedside (132). Even
nucleic acid biomarkers can now be detected within minutes,
with recent publications reporting completion of 30 qPCR cycles
within 54 s (133), certainly fast enough for stroke diagnostics
if the promise of portable devices that might be used at the
bedside (134) are realized. Moreover, nanotechnology offers
the promise of highly multiplexed biosensors capable of rapid
simultaneous analysis of large panels of biomarkers (135), an
important consideration if multiple analytes must be assessed to
provide stroke diagnosis and prognosis.
However, it has to be concluded that none of the candidate
markers described in this review have entered routine clinical use
despite their obvious promise. More work is required before lives
can depend on such measurements.
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